Drugs strengthen Fisons resistance
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Fisons yesterday announced interim profits at the top end of analysts' expectations as it continued to resist the pounds 1.7bn bid from the French- owned US drugs group Rhone-Poulenc Rorer. The main spur to growth came from pharmaceuticals, which saw operating profits leap 31 per cent to pounds 47.6m.
Stuart Wallis, chief executive, said the results from the division "clearly give the lie to the assertion by RPR that our pharmaceutical franchise has stalled." His call to shareholders to continue to reject the bid, worth 240p a share, found an echo amongst shareholders as RPR announced that acceptances at the first closing date covered a mere 0.24 per cent of the shares. But RPR dismissed the figures, highlighting the boost given by a particularly strong hay fever season in Japan, which Fisons admitted had added around pounds 13m to sales and pounds 10m to profits, and the impetus provided by the bid.
Sales of Intal, Fisons' core but ageing anti-asthma drug, fell 9 per cent to pounds 92m, hit by the move off-patent of the nebulised form of the drug in the US last year. Growth of 21 per cent to pounds 25m in its replacement, Tilade, was insufficient to offset the decline.
The failed merger with Medeva cost pounds 3m in fees and other costs, Fisons revealed. It announced an 18 per cent increase in the interim dividend to 2p.
Comment, above
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments